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Abstract
European and international regulation of human health research is typified by a 
morass of interconnecting laws, diverse and divergent ethical frameworks, and 
national and transnational standards. There is also a tendency for legislators to regu-
late in silos—that is, in discrete fields of scientific activity without due regard to 
the need to make new knowledge as generalisable as possible. There are myriad 
challenges for the stakeholders—researchers and regulators alike—who attempt to 
navigate these landscapes. This Delphi study was undertaken in order to provide 
the first interdisciplinary and crosscutting analysis of health research regulation, 
as it is experienced by such stakeholders in the UK context. As well as reinforcing 
existing understandings of the regulatory environment, Delphi participants called 
for greater collaboration, and even co-production, of processes involved in health 
research regulation. On the basis of this research, we offer insights about how health 
research regulation can become a matter with which a wider range of stakehold-
ers—including researchers, regulators, publics and research sponsors—can engage. 
The evidence supports the normative claim that health research regulation should 
continue to move away from strict, prescriptive rules-based approaches, and towards 
flexible principle-based regimes that allow researchers, regulators and publics to co-
produce regulatory systems serving core principles. By unpacking thorny concepts 
and practices at the heart of health research regulation—including the public interest 
and public engagement—our results have the potential to situate and breathe life into 
them. The results also demonstrate that while proportionality is well-recognised as a 
crucial element of flexible regulatory systems, more must be done to operationalise 
this as an ethical assessment of the values and risks at stake at multiple junctures in 
the research trajectory. This is required if we are to move beyond proportionality as 
a mere risk-management tool. Compliance culture no longer accurately reflects the 
needs and expectations of researchers or regulators, nor does it necessarily produce 
the best research. Embracing uncertainty—both as a human practice and a regula-
tory objective—may represent the brighter future for health research.
Electronic supplementary material The online version of this article (https ://doi.org/10.1007/s1072 
8-019-00383 -9) contains supplementary material, which is available to authorized users.
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Introduction
The architecture of health research has vastly expanded over the past two decades, as 
has the range of actors involved. Today, health research integrates studies involving 
tissue, health, lifestyle and genetic/genomic data, metadata and social media content. 
These developments have resulted in a burgeoning of often siloed sets of ‘regulatory 
spaces’ [16, 31], which focus on the nature of the objects of research rather than the 
interests and objectives at stake. There is also an increasing blurring of the distinc-
tions between traditional roles such as clinician or researcher and patient or partici-
pant, not to mention between research and clinical treatment. The focus of enquiry is 
in a broad field termed here ‘health research regulation’. This is not a formal term of 
art, but rather refers to the general ecosystem of activities, laws and regulations that 
seek to shape the conduct of any and all types of research involving human partici-
pants, or materials, data or tissues donated by them. This involves a complex morass 
of regulations and actors, albeit in the European context many legal requirements 
derive from European Union law, as is the case with clinical trials, medical devices, 
data protection, and advanced therapy medicinal products (ATMPs).
It is not uncommon in the realm of human health research for regulators to adopt 
the ‘command and control’ model of regulation, as is commonly understood in regu-
latory theory [4, 30]. This involves a centralised authority, usually wielding legal 
powers of inspection and sanction, to oversee an area of health research. Typical 
examples are clinical trials and reproductive research, as demonstrated by the exten-
sive powers of the UK’s Medicines and Healthcare products Regulatory Agency and 
Human Fertilisation and Embryology Authority, respectively. However, as human 
health research has expanded rapidly in recent decades to involve more work with 
personal data and biological samples (e.g. blood and tissue), this model has not 
been replicated. Rather, more reliance has been placed on regulatory approaches 
such as consent or anonymisation to authorise research. In other words, provided a 
participant consents to their data and samples being used, or the data and samples 
have been anonymised rendering re-identification effectively impossible, research 
may proceed. These approaches, too, however, have met with critics both for inad-
equately protecting and respecting research participants and/or blocking important 
kinds of research [1, 2]. A recent report from the Academy of Medical Sciences [3] 
called for a holistic approach to health research in an attempt to tackle some of these 
challenges, but there remains a lack of evidence and insight as to what form this 
might best take. Accordingly, this Delphi study was motivated by a concern that reg-
ulation of health research in the UK and Europe currently may be failing effectively 
to protect and promote the core values and objective of achieving improvements in 
human health while also responding well to erosion of the traditional socio-legal 
distinctions noted above. This threatens the ability of biomedicine to deliver both 
individual and social benefit. At the same time, the study did not assume that more 
law or regulation is necessarily the answer.
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The key goal of this Delphi study is to provide the first interdisciplinary and 
crosscutting analysis of health research regulation as it impacts on the realisation 
of the goals of health research. It has sought to capture the views and experiences 
of stakeholders—both regulators and researchers—regarding regulation in order to 
inform better policy and legal responses. It aims to expose any gaps between law 
and regulation, on the one hand, and research practice, on the other. It seeks to 
explore opportunities and barriers to move within and between regulatory spaces, 
and to throw light on areas of uncertainty and instability. This study captures evi-
dence of health research regulation as directly experienced by key stakeholders who 
inhabit the ecosystem; this is set against the core concepts and approaches that have 
typified health research regulation to date, notably in the UK and European regula-
tory environments. While the majority of the Delphi participants work in the UK 
sector, it is notable that many laws and regulation on health research emanate from 
the European Union (Box 1). Accordingly, the results have a wider relevance for all 
stakeholders operating within such a regulatory ecosystem.
Methods
Study Design
The Delphi survey technique was chosen because its use of open-ended questions 
minimises bias introduced by the researchers, allowing the research agenda to be 
set by study participants themselves in an area where ‘appropriate historical/eco-
nomic/technical data [is not available] and thus where some form of human judg-
mental input is necessary’ [26: 354]. As defined by standard Delphi methodology, 
the study consisted of an ‘interactive, sequential and multi-step’ characterisation of 
expert views relying on iterative rounds allowing (1) participants to modify their 
responses, (2) controlled feedback of group responses from the previous round to 
Box 1  Key legal, regulatory, social and political events occurring at the time of the Delphi study
The Care Act 2014, which established the Health Research Authority (HRA) as a non-departmental 
statutory body with responsibility for health and social care research governance
The failure of the ‘care.data’ patient data sharing regime and subsequent concerns regarding information 
governance in NHS England
UK implementation of revised Caldicott principles regarding information governance in the health sec-
tor, specifically the handling of patient-identifiable information
Drafting and subsequent implementation of new EU General Data Protection Regulation (Regulation EU 
2016/679)
New EU regulation of clinical trials on medicinal products for human use (Regulation EU 536/2014)
New EU regulations of medical devices (Regulation EU 2017/745) and in vitro diagnostic medical 
devices (Regulation EU 2017/746)
Changes to HRA regulatory approvals system, namely HRA Approval, bringing together the assessment 
of governance and legal compliance
Brexit (i.e. the potential withdrawal of the United Kingdom from the European Union)
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give participants an idea of the panel’s aggregated views, and (3) quasi-anonymity 
[6, 25]. Quasi-anonymity means that the participants were fully anonymous to each 
other as well as to the whole research team, except for the study coordinator who was 
responsible for all information exchange. This allowed the participants to express 
themselves frankly and free of the peer-group pressures and other social dynamics 
inherent in non-anonymous group discussions. Ethics approval was granted by the 
University of Edinburgh Law School Research Ethics and Integrity Committee.
Experts were selected by the research team using purposive sampling. They 
were mostly—but not exclusively—based in the UK. The individuals who agreed 
to participate in the study described their primary professional responsibilities in 
their own words (see below), on the basis of which they were categorised as either 
a researcher, a clinician or a regulator, with some participants claiming primary 
responsibilities falling under more than one of these three categories, thus reflecting 
the hybrid nature of their work. In this small-scale piece of research, we did not seek 
to recruit patients or members of the public, whose responses might also be more 
fully captured using qualitative interviews.
The study comprised three rounds in order to provide enough opportunity for the 
participants to modify their responses in light of their participation in the Delphi 
exercise, as well as to avoid attrition due to too many rounds [5, 9, 26]. Rounds 2 
and 3 of the survey included questions about participant’s experiences of the cur-
rent research culture and instances of best practice; their attitudes to risk-based 
approaches to regulation; their opinions on how to achieve regulatory efficiency 
and responsive regulation; their thoughts on public interest and the role of public 
engagement; and finally how they saw the future of health research regulation.
The study was run via the Bristol Online Survey tool, each round running for 
7 weeks and spaced 6–10 weeks apart. Up to 2 additional reminders were sent to 
experts for each round. No financial incentives were offered for participation.
105 experts (roughly equal numbers of men and women) were invited to partici-
pate in the first round, and 29 completed it. Of these, 23 completed round 2, and 
20 completed round 3. Of the final 20 participants, 17 were from the UK, 6 were 
female. As their primary professional responsibilities, 10 of the final participants 
named ‘research’ activities (in health and in the social sciences), 7 named regulatory 
activities, 2 clinical duties, and 1 named both research and clinical duties. Of the 9 
participants who did not complete all three rounds, 3 were researchers, 1 a regulator, 
and 5 were hybrid researchers/regulators. Table 1 presents the participants’ charac-
teristics in more detail.
Process
Round 1 ran from April to June 2017 and consisted of 14 open questions regarding 
the research topic and an additional 8 socio-demographic questions. 29 participants 
contributed a total of 396 responses to the 14 open-ended questions consisting of a 
total of 26,246 words.
Round 2 was built based on the first-round responses and resulted in 70 7-point 
Likert scale questions and 5 multiple choice questions organised into 10 sections. It 
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ran from August to October 2017. Participants were encouraged to leave qualitative 
comments to justify their quantitative response. These 23 participants contributed 
615 comments consisting of 15,015 words.
Round 3 ran from November 2017 to January 2018. It consisted of 39 of the 75 
questions from round 2 presented together with the mean second-round response for 
Likert scale questions and the frequency with which multiple choice responses were 
chosen and the qualitative comments from round 2. 36 questions were omitted in 
round 3 because sufficient homogeneity in second-round responses was observed. 
6 of the 43 questions had slight modifications or additions made to the wording to 
address concerns about ambiguities that participants raised in round 2. An addi-
tional 5 novel qualitative questions were added in round 3 to explore salient themes 
in more depth. The remaining 20 participants contributed 384 comments consisting 
of 11,608 words.
Qualitative Analysis
In addition to the quantitative results generated by the study, as reported in “Public 
Engagement” section, qualitative data was generated by the study and analysed by 
the project team. Following Braun and Clark [7], this approach involved:
• Familiarisation with the data—including reading, re-reading and noting initial 
impressions of the data, first by the whole project team, before sections of the 
study were allocated to specific team members.
• Coding the data—in this process each team member reviewed the sections 
for which they were responsible in order to identify portions of the text with 
labels. At this stage, these labels were as specific or broad as required, with 
a view to some of the categories being collapsed as the analysis progressed. 
Table 1  Participant characteristics (n = 20 in round 3)
Age










Clinical Neurologist, Data Access Consultant, Ethical Review, Health Service Data Protection, Neu-
roradiologist, Oversight of Primary Care Service Organization, Project Management, Public Health 
Consultant, Research (Biomedical Ethics, Biotechnology, Imaging Research, Law (2), Political 
Science, Population Health Data, Population Health Genetics, Social Psychology, Sociology), Stake-
holder Engagement, Training for REC members
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Some of these codes were based on existing research interests, but a signifi-
cant proportion emerged inductively from the data.
• Collating codes into broad themes—here codes were arranged by broad 
themes and any redundancy eliminated, again by the allocated team member.
• Reviewing and revising—this was the most labour-intensive part of the pro-
cess. Here the themes and codes generated in the primary analysis were cross-
checked in detail by a second team member, and then discussed as a group. 
This ensured that further, cross-cutting themes could be identified and allowed 
for adjustments to be made to themes and codes, ensuring that nothing of 
importance was missed.
The seven key themes that were identified in this qualitative analysis are reported 
upon below in the “Conclusion” section.
Summary of Quantitative Results
Of the 75 Likert statements rated over rounds 2 and 3, 7 garnered agreement or 
strong agreement (6 or 7 on a 7-point scale) from more than two-thirds of the par-
ticipants. Of the 6 multiple choice lists, 4 lists had items selected as most impor-
tant by more than two-thirds of the participants. The following is a breakdown of 
these results.
The greatest agreement (80% of the participants selecting 6 or 7) was with the 
concept that ‘the risk of not conducting research must be managed as assiduously 
as the risk of conducting research’.
Three of the seven items that reached some consensus had to do with obstacles 
to optimal health research regulation:
• ‘Inconsistent application of data protection legislation and regulation creates 
barriers to data access in health research’ (75%);
• ‘Values such as the public interest and public benefit as used in health regula-
tion need further elaboration in practice’ (73.9%);
• ‘Rigid legislation can distract decision-makers from considering the overall 
intention of legislation.’ (69.6%)
The remaining three items highlight specific ways of improving health research 
regulation:
• ‘Training on information governance ought to be offered to researchers’ 
(75%);
• ‘Health research regulation would benefit from the inclusion of best practice 
examples, which can help researchers, RECs and others understand how princi-
ples should be applied’ (73.9%);
• ‘Public engagement activities should involve individuals other than patients.’ 
(70%)
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The 4 lists yielding items selected by more than two-thirds of participants can be 
seen to supplement these 3 items. ‘Best practice examples’ should be ‘identified’ 
by ‘regulators’ (85%) and ‘researchers’ (75%), and ‘consensus’ on these examples 
should be ‘reached’ by ‘regulators’ (90%), ‘professional bodies’ (85%), ‘researchers’ 
(80%), ‘patients/participants’ (80%), and ‘publics’ (80%). The most important ‘aim 
of public engagement activities’ in health research was deemed to be ‘allowing the 
perspectives of persons with experience of a condition or intervention to be heard’ 
(85%).
‘Conditions most important to expedite review of urgent research’ were deemed 
to be:
• ‘Clearly defined requirements/expectations of what is required’ (73.9%);
• ‘Protection of research participants from harms’ (73.9%);
• ‘A channel for expedited review for urgent research.’ (73.9%)
Disagreement
In addition, five areas with significantly divergent views within the participant panel 
were identified, i.e. at least a quarter of the panel agreed with the statement and 
at least a quarter disagreed. Three of these were related to the purpose of health 
research regulation:
• ‘Regulatory frameworks help researchers to focus on delivering public benefits 
and interests’;
• ‘Health research regulation currently encourages ethical reflection by research-
ers’;
• ‘Priority is split between delivery of a streamlined regulatory system and 
attempting to improve the ethical awareness and skill-base of health researchers.’
The panel was similarly split regarding the idea that ‘a system of “trusted 
researchers” should be developed to allow fast-track approvals’ as well as on 
whether patients and publics should be involved in the following stages of the health 
research process: ‘methodology decisions’, ‘drafting grant applications’, and ‘inter-
preting the results’. As reported below, we explored these last themes more fully 
with the participants because they represented unexpected results.
Summary of Qualitative Results
Regulatory Uncertainty
The responses to the Delphi survey capture a core, recurrent theme that cuts across 
the regulation of health regulation, namely uncertainty [29, 30]. Uncertainty, 
of course, can arise in multiple forms in this field; research by its very nature is 
an uncertain endeavour. Yet, here we found that particular concern was largely 
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expressed about researcher confidence in correctly interpreting, and thus comply-
ing with, regulation. That is, the uncertainty was not about research itself, but rather 
about the rules and regulations that must be observed in order to conduct lawful 
and ethically acceptable research. We can thus derive two sub-themes from the 
responses. First, inefficient legal responses to uncertainty [30] mean that those who 
fall within the rubric of regulatory rules are often left with various difficulties about 
how to navigate them. Second, some participants reported that the law is creat-
ing uncertainty for various ‘partners’ in the health research process, especially for 
researchers.
Of the forms of uncertainty that might be experienced by stakeholders, one per-
sistent theme that arose from the participants’ responses related to the ways in which 
regulations and guidance are interpreted, especially where regulatory provisions are 
cross-cutting or operate in overlapping ways. For example, some respondents offered 
the view that law can be too generic, leaving researchers uncertain as to whether law 
even applies to them. An example, consistent with wider commentary [11, 21] is the 
thorny subject of data protection as it relates to health research. As also reflected in 
the quantitative data, participants reported confusion around the provisions of the 
new General Data Protection Regulation (GDPR) with regards to research exemp-
tions and the requisite levels of consent (see Box 1). Discussion of the GDPR also 
highlighted the challenges which frequently-changing legislation can present for 
actors in understanding their responsibilities. A tension emerged between, on one 
hand, suggestions that regulators ought to do more to support sponsors and research-
ers, and on the other hand, that sponsors ought to take on more responsibility in 
terms of supporting researchers. Likewise, it was suggested that regulators have a 
responsibility to be clear about which activities are prohibited and permitted. As 
shown more fully below, this emphasises a common theme to emerge from this 
study around the idea and importance of collective responsibility in health research 
regulation.
The survey also found that researchers often feel uncertain as to whether their 
proposed project complies with one or more regulatory framework, especially when 
new forms of research and/or innovation do not seem to fit neatly within a given reg-
ulatory framework. New projects may overlap multiple guidance/policies/regulatory 
spheres: ‘Complex research is often faced with such uncertainty: examples include 
where research purposes seem to straddle research/clinical boundaries such as in 
genomics of rare diseases’ (21, researcher).1 Further, some participants expressed 
concern that guidance is easily misinterpreted, especially if a given law is complex: 
‘Regulatory frameworks can be pretty hard to understand. Categorisation of research 
practices within frameworks is a key problem’ (30, researcher). The Delphi results 
reflected a call for language used in regulations and/or guidance to be clear, acces-
sible and specific. Some respondents reported that language used in regulation could 
become obsolete if too specifically tied to particular technologies. Equally, partici-
pants did recognise the need for technology-specific regulation in certain cases. The 
1 Quotes are labelled with a participant’s number (to maintain anonymity) and their professional role 
(see “Methods” section).
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challenge is to develop regulatory frameworks that can adapt to reflect more recent 
uses of words and phrasings often employed in health research environments. This 
issue emerged as part of a larger call for regulation to be more responsive to new 
forms of research as well as new challenges, as we discuss further in “Flexibility” 
section.
Yet, not only did results show uncertainty surrounding the interpretation of, and 
compliance with, particular rules, but also, more broadly, with general principles of 
health research regulation. For example, participants expressed difficulties in under-
standing where the public interest lies in health research regulation. In particular, 
results highlighted a perceived lack of relevance of abstract legal notions of public 
interest to health research regulation: ‘Public interest seems too nebulous, residing 
in case law and judges’ superior consciousness’ (20, clinician/researcher). Uncer-
tainty around legal notions of the public interest can obstruct otherwise beneficial 
health research. Furthermore, there was doubt about how public interests relate to 
public engagement: ‘Values such as the public interest and public benefit as used 
in health regulation need to be specified much better’ (10, researcher). We return to 
these concepts in “Public Interest” section. For now, the challenge to emerge is two-
fold: while clearer conceptualisation of public interest is required, it has also been 
suggested that public involvement/engagement is required to feed into any future 
conceptualisation. In other words, these regulatory concepts or approaches do not 
exist in isolation: they influence and are formed by each other. While this might be a 
truism in the abstract, it has a tendency to create more uncertainty within regulatory 
environments in practice, and generates a degree of anxiety about what and who is 
implicated in such processes.
The ability of stakeholders to appropriately identify and discharge the responsi-
bilities incumbent upon them is reliant at least in part upon the existence of clear 
legislation within the regulatory setting. However, as we shall see below, legislation 
is only one means of guiding researchers’ practices (see “Roles and Responsibilities 
of Key Actors in Shaping the Regulatory Framework” and “Flexibility” sections). 
Respondents provided examples from across the research spectrum where unclear 
legislation raises uncertainties around how, and in what circumstances, they ought to 
act, for example when reporting adverse events. A strong theme to emerge from our 
engagement with participants was the role of sponsors in this regard. As one partici-
pant stated: ‘I can see what the regulations are trying to do but they are very burden-
some, prone to overinterpretation by sponsors, this muddies the research and thus 
does not enable researchers’ (25, researcher). The same respondent argued, ‘Rigid 
application of regulations by some sponsors risks absolving the researcher of any 
moral responsibility—certainly does not encourage it—and becomes a tick box pro-
cess which is dangerous.’ This suggests that attention needs to be paid to bottleneck 
moments in regulatory timelines; sometimes, upstream actors can significantly delay 
or otherwise adversely impact effective regulation in ways that are not transparent or 
obvious to regulators and other stakeholders.
Two final themes that emerged among the responses regarding uncertainty and 
interpretation were the need for researchers themselves to take individual and col-
lective responsibility for the interpretation of law, but participants also reported the 
need for support in this interpretive endeavour. It thus seems that there is a balance 
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to be struck here between supporting researchers and asking them to act autono-
mously. All balancing exercises require a degree of judgement, and in the next sec-
tion we address one of the more concrete concepts that requires this of stakeholders: 
proportionality.
Proportionality
Proportionality in health research regulation has long been a clarion call among 
many stakeholders, from regulators and regulatees alike [2]. Indeed, its role in deliv-
ering effective regulation has taken on the mantle of a self-evident truth in the litera-
ture as well as policy and practice circles: who would advocate for a disproportion-
ate system? Multiple examples now exist of attempts to incorporate proportionality 
into regulatory regimes, including the UK’s REC proportionate review service [14], 
which allows for expedited ethics review if there are ‘no material ethical issues’ in a 
proposed research project.
However, the reality of attempting to give effect to proportionality in practice is 
far more nuanced than a simplistic cost/benefit balance might suggest, and this has 
resulted in subtle distinctions in understanding and experience. For example, the 
Delphi survey participants reported that while proportionality has increased, the 
overall complexity of the systems has also increased. There was a sense that this has 
occurred independent of assessments of actual research risk, and that regulation has 
increasingly taken on the form of ‘form filling’.
This raises the crucial question: what kind of exercise is the pursuit of propor-
tionality anyway? It can be easy to reduce this to a techno-bureaucratic risk/benefit 
assessment, but this misses the fact that the search for proportionality is a moral 
assessment of whether, when and how to proceed in the face of uncertainty. As 
another participant commented: ‘[c]urrent frameworks distract researchers with pro-
cess detail which detracts from the quality of the science, delays progress, wastes 
money and may actually increase the risk to participants’ (25, researcher). Conduct-
ing research in a way that contributes to the creation of social value is also itself a 
moral matter. As other participants commented on regulatory regimes: ‘…bureau-
cracy and frameworks can stand in the way of creativity and innovation…’ (15, cli-
nician), and also ‘…adding value by subtracting adverse impacts seems scalar but 
is more complex: it may also limit research directions (e.g. constraints on research 
involving children)’ (24, regulator). A further participant put it simply thus: ‘The 
risk of not conducting research is an ethical issue and therefore should be taken into 
account’ (21, researcher).
There is an understandable tendency when engaging with proportionality to see 
this as a risk-based assessment. But, as the above responses demonstrate, proportion-
ality is more than mere risk-management. Diverse research protocols involve a wide 
range of considerations, for example there may be harms to participants or groups that 
go far beyond the physical, such as identity harms [24]: ‘…risks are not just physical 
(e.g. for forearm studies). The psychosocial risks of less invasive research should not 
be underplayed’. In contrast, some outcomes—such as imminent death in emergency 
situations—can lead to tolerance and acceptability of very high-risk interventions [12]. 
1 3
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Delphi participants picked up on these points in various ways. For example, ‘[m]any 
actors (e.g. NHS regulators) tend to be risk averse and this can prevent useful research 
where the risk is less than perceived’ (19, regulator), while at the other end of the spec-
trum it was also commented that ‘… [w]ell established simple interventions can involve 
very considerable risk. Researching complexity can be difficult for biomedical research 
focused committees to understand, as indeed can straightforward qualitative research; I 
would not want to see more obstacles placed in the way of such work’ (15, clinician).
More presciently, the following important point was made about the generalisable 
nature of all research activity: ‘It is less likely that the procedures applied to research 
participants will get substantially more complex; rather than complexity lies in what 
happens to the data derived from them; where it goes, how it is used now and in future’ 
(5, researcher). This highlights crucial questions about the stages in the research life-
cycle at which assessments of proportionality are carried out. As we have argued else-
where, the timeframes involved in realising the social value of human health research 
are often extremely attenuated, and the range of actors involved in these processes are 
diverse and often unconnected [13]. This has implications for regulatory pathways 
and the—perhaps repeated—role for proportionality therein. The reporting of adverse 
events was frequently seen by Delphi participants to be a downstream disproportionate 
activity:
…the definitions of adverse events result in vast numbers of daily events being 
classed as reportable with result that trial gets bogged down in documenting the 
utter unrelated trivia that are common in patients with some disorders and unre-
lated to the drug to the neglect of collecting complete and high quality baseline 
and outcome data on which the reliability of the results depend (25, researcher).
As to ways to navigate increased complexity—and to manage proportionality effec-
tively—some important ideas emerged from the research. One participant advocated 
‘regulators etc. becoming helpers and guiding processes to make approval more feasi-
ble. Whilst having a proportionate outlook’ (27, clinician). This has resonance with our 
own argument for an increased role for regulatory stewardship to help guide researchers 
through regulatory landscapes [19]. Others called for ‘networked governance’ whereby, 
among other things, ‘…regulatory agencies in health (broadly understood) would need 
to engage more with academics and charities, and to look to utilise a broader range of 
expertise in designing and implementing governance strategies and mechanisms’ (5, 
researcher).
This points beyond proportionality to matters of how to assess the public interests at 
stake, and we now turn to this theme, drawing on the findings from “Regulatory Uncer-
tainty” section about the utility of appeals to public interest and its seemingly eternal 
amorphous nature.
Public Interest
The Delphi participants recognised that one of the key challenges of realising val-
ues such as ‘public benefit’ and ‘the public interest’ is the need to take into account 
various interests of diverse publics and other stakeholders. It was noted that these 
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interests might run contrary to one another or appear to be mutually exclusive (19, 
regulator). A particular concern was the very practical issue of how to capture the 
range of opinions engaged in health research regulation. For example, one partici-
pant noted that ‘…the loudest voices aren’t the ones that we need to listen to’ (6, 
regulator). Some commented on the risk that small but vocal groups might dominate 
the discourse on health research (with the corollary implication that there would 
be other voices that would not be heard) (20, clinician/researcher). Together, these 
highlighted to us the relationship between the role of the public interest, as a con-
cept, and the potential role of ‘good’ public engagement to inform and interact with 
this concept. We discuss this topic further in “Public Engagement” section.
Some were of the view, more generally, that health research is very (perhaps 
overly) focused on the individual participant. It was suggested that this ‘…was 
understandable but not always helpful and often to the detriment of other legitimate 
interests’. When considering this tension others urged that ‘…there should generally 
be more attention to the public/social level of benefits and harms, in addition to the 
individual level’ (16, researcher).
To find a way forward, participants looked to transparency—both of process and 
of values—as part of the solution. One participant noted that giving an acceptable 
account of how different views, and in particular minority views, were taken into 
account in health research is crucial (24, regulator). Another elaborated on this 
theme, suggesting that research is based on trust, which will be ‘…best promoted 
by involving all those with legitimate interests’ (2, regulator). Comments included 
that it was ‘important for researchers to be able to explain and justify their work 
in lay terms’ (19, regulator), acknowledging that there had been some, albeit slow, 
improvement here. This has resonance with the findings explained in “Regulatory 
Uncertainty” section that suggest a need for all stakeholders to engage in the col-
lective responsibility of giving effect to regulatory concepts and tools, such as the 
public interest.
As noted above, in the report of the quantitative findings from the study, there 
was strong agreement by the participants in relation to the statement that: values 
such as the public interest and public benefit as used in health regulation need fur-
ther elaboration in practice. This was also reflected in the qualitative data where 
the need for researchers to be able to articulate the public benefit and public inter-
est in their work was addressed specifically by a number of participants (17, regu-
lator and 21, researcher). One participant’s experience was that ‘…researchers are 
often poor at being able to articulate the public interests and benefits in their work, 
making their application seem riskier’ (17, regulator). Others suggested that this 
might be because the benefits of research could sometimes be taken for granted (16, 
researcher), hence the focus instead on preventing harm. A specific example given 
of where this might be difficult related to commercial players in health research. 
The view was expressed that the new GDPR would bring the ‘articulation of pub-
lic interest for data processing into sharper focus’ (21, researcher). Another concern 
was that these concepts were too nebulous. Some called for greater clarity, ‘…in 
both a conceptual (in relation to other key values and concepts) and a situated sense 
(within the context of particular research initiatives)’ (24, regulator), again echoing 
the findings in “Regulatory Uncertainty” section.
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Achieving clarity around public benefit and public interests was acknowledged to 
be a challenge (24 regulator and 16 researcher). However, when looking forward to 
possible futures for health research regulation, participants argued for more empha-
sis on this, and for health research to support these values. As one participant noted: 
‘We need the key voices of health…being publically supportive of research and 
good examples of the value it brings to individuals’ (13, regulator). Examples given 
of these ‘key voices’ included the Chief Medical Advisor to the UK government and 
the CSO (Chief Scientist Office) in Scotland. As well as this call for further articula-
tion of the value of research, it was recognised that governance strategies and mech-
anisms would be required to support this work.
Public Engagement
As highlighted in “Public Interest” section, the Delphi study generated evidence of 
the importance of appreciating the mutually complementary roles of public inter-
est and public engagement. This is a direct reflection of the growing recognition 
that patients and members of the public can play a role in various, but not all, areas 
of medical (and other science) research [15, 22]. This role is usually described as 
public engagement or involvement in research. Many of the Delphi participants 
responded to our questions about public engagement by discussing public-patient-
involvement (PPI) or public involvement (PI) instead. However, despite this inter-
changeable use, one respondent commented that ‘engagement (not involvement) is 
for everyone. The two things aren’t the same by the way’ (5, researcher). Although 
both are more active than awareness or understanding, only involvement suggests 
participation in the research process itself.
Underlying this inconsistency in terminology is a lack of shared understand-
ing about who counts as ‘the public’. Answers referring to ‘broader publics (8, 
researcher)’, ‘harder to reach people and groupings’ (19, regulator) and ‘patients and 
potential patients’ (24, regulator) all acknowledge that the public is not a homogene-
ous entity. Despite the often stated argument that ‘we will all be patients one day’ 
(25, researcher), the public cannot be easily equated to (potential) patients: as one 
respondent argued, patients and potential patients have ‘complex priorities, [that 
are] sometimes in conflict’ (24, regulator). Although patient involvement is becom-
ing a more routine part of medical research, respondents described how ‘the same 
token patients’ attending meetings ‘tend to be white, retired and middle class’ (6, 
regulator). This a problem across many kinds of engagement initiatives that rely on 
voluntary participation. Individuals who have the resources to participate in such 
activities are usually educated and articulate [8], leading to the danger that the needs 
and priorities of other groups are not recognised. Future research needs to go beyond 
generic questions about public engagement and look at the possibilities for partici-
pation in specific contexts, including identifying which groups are missing out. The 
‘difficult to reach’ can quickly become the ‘easy to ignore’.
It was suggested that there might be a role for ‘deliberative research’ methods 
here, as well as room for more public engagement in multiple research settings and 
at different stages of the research enterprise. Successful public engagement was 
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defined as ‘facilitating two-way understanding’ (5, researcher) between researchers 
and publics. Ideally, such conversations give members of the public a better under-
standing of the benefits of research, how it is practised and some of the constraints 
involved. At the same time, dialogue with non-researchers also allows researchers 
to develop a better understanding of what (some) publics want from research, espe-
cially the types of research they deem important. Some respondents did fall back 
onto ‘deficit’ models [10] to argue that, because of a lack of technical knowledge, 
members of the public should not be asked for advice about research funding priori-
ties. However, several other participants in the Delphi study made the opposite point 
that listening to a wider range of viewpoints and incorporating them into research 
policy or designs can improve research. However, this is a time-consuming process, 
not least because it requires trust to develop between researchers or clinicians and 
their publics [20], and so the pursuit of meaningful public engagement adds to both 
the direct and transactional costs of research projects. Many funders now expect 
research projects to include an element of public engagement, but our data suggests 
that this still goes against established ways of working within medical research. Not 
only will researchers have to develop new ways of writing grants and academic arti-
cles, but as one respondent suggested: ‘we need to be given the institutional license 
to do this and to make mistakes and try new things. Otherwise it’s too risky to our 
careers’ (5, researcher). If success can no longer be understood solely within a scien-
tific model of ‘hard evidence’, then new ways of conceptualising of what it means to 
do good research must be developed. One such means is co-production, which forms 
the focus of the next section.
Roles and Responsibilities of Key Actors in Shaping the Regulatory Framework
Co-production and collaboration at different junctures of the health research endeav-
our emerged as important themes within the survey, implying that a variety of stake-
holders have a role to play in shaping the regulatory framework. From the perspec-
tive of public and patient involvement, this is in keeping with a wider shift towards 
increased stakeholder engagement (see “Public Engagement” section above). The 
findings also demonstrate acknowledgement that the development of regulatory 
approaches ought to involve partnership between regulators and researchers. This 
relationship was described as essential in order to achieve regulatory efficiency and 
in the identification of, and reaching consensus on, instances of best practice. One 
respondent explained that such collaboration between regulators and experienced 
researchers could provide the context-sensitivity necessary to develop best practice 
(24, regulator), an important function of best practice which has been considered 
elsewhere [28].
While there appeared to be a general appetite for the inclusion of stakeholders, 
interesting nuances emerged around which stakeholders ought to be involved in dif-
ferent processes, and what weighting their preferences ought to be given (16 and 30, 
researchers). For example, some respondents suggested that potential roles for pub-
lics and patients in shaping research were context-dependent, as described in “Pub-
lic Engagement” section.
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One way in which roles and responsibilities, permitted and prohibited activities, 
as well as instances of best practice can be communicated to researchers, is through 
training. Respondents were surveyed on their attitudes towards the prospect of 
requiring accreditation of researchers in order to grant them ‘trusted’ or ‘accredited’ 
status which could lead to fast-track oversight of research applications. However, 
this was met with a mixed reaction; although some participants thought accredita-
tion could improve flexibility and responsiveness, a considerable number expressed 
scepticism, arguing that accreditation might create a power imbalance between 
accredited and non-accredited researchers and lead to possible lapses in oversight. 
Would an accredited researcher be audited? Would it lead to an ‘old boys’ network? 
Others felt that accreditation could be misplaced, perhaps serving only to gauge the 
researcher’s character or track record to date, rather than the appropriateness of the 
research design and research system as a whole. Consequently, a few participants 
advocated a mixed accreditation system for certain areas of research where both 
researchers and sponsors are accredited and subject to regular review and audit. This 
did not extend, however, to Phase 1 clinical trials or research involving vulnerable 
persons.
Flexibility
There was concern that the health research regulatory system as it currently func-
tions is too rigid; what participants desired was a flexible system, built less around 
command-driven rules and more on proportionate but clear high-level principles 
that are facilitative of research (5, researcher and 6,). Just as respondents advocated 
for greater certainty in regulation, so too did they call for regulation that permitted 
them a wide regulatory space in which to operate. Certainty and flexibility in regula-
tion were not seen as mutually exclusive principles. As also noted in the quantita-
tive results, the Delphi survey participants emphasised the importance of systemic 
approaches in regulation, and the need for a robust architecture that supports the 
various component parts working in harmony.
For example, some participants felt that sponsors of research projects (e.g. univer-
sities, NHS trusts, pharmaceutical companies) take a strict interpretative approach 
to regulation, which encourages a disproportionate, ‘tick-box process.’ This is illus-
trated most starkly in the requirements for reporting adverse events in clinical trials 
of an investigational medicinal product (CTIMPs). As noted above, requirements to 
report minor adverse events that are not necessarily relevant to the research aims can 
mean that critical tasks such as the collection of complete and high-quality baseline 
and outcome data—on which the reliability of the results depend—get neglected. 
This ‘mismatch’ between what clinical researchers see as contextually serious, and 
what the regulations define as necessary to report, can lead to clogged regulatory 
spaces and research projects tangled in a regulatory mire [30]; see also [18]. Partici-
pants voiced a preference that each step of the regulatory process be more carefully 
managed, with a view to bringing the research project to fruition—and then sus-
tained through completion—as ethically and efficiently as possible.
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To overcome rigidity and the sway of a tick-box approach, some participants saw 
flexibility as a core component of ‘principles-based regulation’, which is seen as 
a beneficial, but not problem-free, regulatory approach in health research. Princi-
ples-based regulation involves regulators outlining principles to achieve regulatory 
objectives and values, and regulatees then devising their own system to serve the 
principles [4, 27]. Within such an approach, regulation could become more adap-
tive to emerging technologies and encourage researchers and sponsors to engage in 
ongoing conversations with regulators on ways to manage risks and achieve defined 
regulatory objectives. Others argued that flexibility works best in a hybrid regula-
tory system comprised of both principles and rules. As one participant put it, ‘prin-
ciples-based approaches offer greater flexibility but [the principles] need [to be] 
interpreted. They work best when they are translated into rules-based guidelines that 
are revised and updated at sensible intervals. You need both [principles and rules] 
working in tandem’ (5, researcher). Similarly, and reflecting the observation that 
certainty and flexibility need not be mutually exclusive, another participant stressed 
that they liked ‘the idea of flexible principles, but this relies on training and time to 
reach consensus. Clear rules are more easily applied when resources are limited’ 
(15, clinician). This would suggest a regulatory design that allows for both certainty 
and flexibility, depending on factors such as resource constraints and stakeholder 
demand. However, others felt that too much emphasis on rules as a means of provid-
ing clarity would not unclog the regulatory space in health research. Instead, these 
participants stressed the need for proportionate and flexible approaches, and for reg-
ulators to encourage researchers and sponsors to adapt approaches that work best 
for them, albeit within an architecture that provides structure and ethical bounds of 
what is considered safe and responsible behaviour.
Together, these narratives simultaneously underlined the potential difficulties of 
reaching consensus in our pluralistic society, as well as the crucial importance of 
cooperation and co-production in research design and delivery.
Looking to the Future
In addition to the principal broad themes detailed above, a number of other issues 
were raised by participants in the study. These are worthy of attention because they 
speak pointedly to the time and political climate in which this study was conducted.
A particular issue that was raised was the role of artificial intelligence (AI) 
or machine-learning in health research and healthcare. Examples of the possi-
ble uses of AI in health research include its application in identifying patterns 
within or between large datasets, and in helping to identify suitable participants 
for clinical studies [23]. Respondents to this study recognised the potential ben-
efits of AI to health research regulation itself, for example to enhance regula-
tors’ realistic assessment of research risks. Nevertheless, it was also recognised 
that the use of AI itself carries ‘very substantial risks’ (15, clinician) arising 
from, for example, the incorporation of ‘deliberate or unconscious biases in the 
design of the tasks, functions and priorities of machine learning systems’ (5, 
researcher), a lack of transparency and difficulties locating ethical responsibility 
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for decisions reached on the basis of AI analyses. As such it was noted that the 
use of AI in healthcare should also itself be the subject of research to better 
understand the incidence and management of these risks. Within the bigger 
picture of health research regulatory environments, AI is a notable example of 
the disruptive impact of new technology on health research regulation, but is 
merely the latest illustration of the on-going uncertainty of the regulatory enter-
prise itself. This feature will never be eliminated, but our study suggests ways in 
which uncertainty and opportunity can be better accommodated within adaptive 
regulatory structures as part of cooperative partnerships between stakeholders.
The importance of regulators establishing regulatory connections, particu-
larly with regards to supporting cross-border collaboration, was raised by partic-
ipants. This was discussed with specific reference to the challenges of working 
across different legislative jurisdictions, for example in multi-centre trials. This 
issue has become particularly acute in the context of the disruptive effects of the 
United Kingdom’s potential departure from the European Union. Yet again, the 
overarching concern amongst participants was uncertainty, this time about what 
the UK regulatory landscape would look like post-Brexit. Some participants sug-
gested that Brexit could provide an opportunity to revisit what ‘right regulation’ 
(30, researcher) might look like. Meanwhile, others expressed concerns that it 
could instead bring ‘change, but not necessarily for the better’ (16, researcher), 
by inviting chaos and ‘a race to the bottom’ (2, regulator) in terms of regula-
tory standards. Participants reported that ‘another worrying aspect of Brexit’ 
(17, regulator) was the threat it posed to much-needed international collabora-
tion between research regulators. Indeed, in disentangling its health research 
regulation from European legal frameworks, while also seeking future regula-
tory alignment, the UK is at risk of creating ‘liminal hotspots’ in a number of 
fields, including the regulation of clinical trials and licensing of medicines [17]. 
These hotspots will be characterised not only by the present uncertainty engen-
dered by transition towards an unclear goal, but also the future threat of ossified 
replacement laws that fail to evolve in step with the rest of Europe. This would 
represent the antithesis of the clear call for readily-interpreted and responsive 
regulation emerging from this research.
These examples are particularly pertinent given the emphasis that our par-
ticipants placed upon clarity and consistency in the application of regulations 
and the value of regulatory systems that are both proportionate and sufficiently 
flexible to be responsive. These goals are not necessarily mutually exclusive 
objectives as some might assume. Underpinning this research is a sense across 
all stakeholders of a common purpose and a willingness to try. Law and regu-
lation must not stifle that commitment with excessive rigidity or the prospect 
of undue sanction. Compliance culture no longer accurately reflects the needs 
and expectations of researchers or regulators, nor does it necessarily produce the 
best research. Embracing uncertainty—both as a human practice and a regula-
tory objective—may represent the brighter future for health research.
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Conclusion
This Delphi study was undertaken in order to provide an interdisciplinary and 
crosscutting analysis of health research regulation as it is experienced by regula-
tors, researchers and other expert stakeholders. The results outlined above pro-
vide five important new insights into the operation of current UK and European 
regulatory environments. A key theme emerging from participants’ responses is 
a call for greater collaboration, and even co-production, of research regulation 
by various stakeholders, in the service of achieving a responsive, flexible and 
proportionate response to the challenges and critical value that health research 
offers. Future research should complement this perspective by investigating the 
responses of other key stakeholders—including patients and members of various 
publics—to this call.
First, our participants argued that lawmakers and regulators should continue 
to steer health research regulation away from a strict, prescriptive rules-based 
regime, and towards flexibility and a principles-based regime allowing research-
ers to co-produce their own systems with other stakeholders and to serve core 
principles. Such flexible approaches enable regulation to be more adaptive to 
emerging technologies, and also encourage researchers and sponsors to engage 
in ongoing conversations with regulators in order to manage risks and achieve 
defined regulatory objectives. These conversations, in turn, allow for the practice 
of systems of regulatory stewardship, where regulators work with researchers and 
sponsors to work through the different stages of the regulatory process efficiently, 
ethically and legally.
Second, many respondents also highlighted the uncertainty that researchers 
experience in interpreting and, therefore, properly complying with regulations. In 
such cases, a key issue is the need to strike a balance between attributing respon-
sibility for the interpretation of law, and the provision of support in carrying out 
that interpretation. Although practices of regulatory stewardship may be one 
means of addressing this uncertainty, our findings suggest that a further explora-
tion of both effective means of collaborative modes of regulation and the pursuit 
of a fresh understanding of proportionality might inform us how to better meet 
this need.
Third, the call for greater mobilisation of collaboration and co-production 
implies a diffusion of responsibility whereby regulation becomes the common con-
cern of a range of actors—including researchers, regulators, publics and research 
sponsors. At the same time, it is clear that these different groups cannot all partici-
pate in all stages of the regulatory process to the same degree. For example, the 
principle of wider public (and other stakeholder) engagement and involvement in 
regulation is broadly accepted. However, our results demonstrate that debates are 
still taking place about: what form this participation should take; which individu-
als and groups should be encouraged to participate; at what stage of the research 
cycle it is practical for them to do so; and how much weighting the preferences of 
each of these stakeholders ought to be given. Answers to these questions will vary 
depending both on the type of research in question and on the specific stakeholder 
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group in question. This emphasises the importance not only of the who question in 
engagement, but also the when. If engagement is to be meaningful, its undertak-
ing must be timely with respect to both when engagement takes place, and what is 
then done with the findings to improve regulatory processes.
Fourth, this study also provides a situated account of what public interest 
means to stakeholders in regulation. Achieving a better understanding of the 
public interest is an important element of the guiding principles underlying col-
lective responsibility. Like public engagement, public interest is always context-
specific. More specifically, participants pointed to the ways in which techniques 
of public engagement can feed into our understanding of how the public inter-
est is accomplished in practice. The results emphasised the need for transparency 
when trying to establish its meaning in a particular context, for example through 
the articulation of the value of research and the benefits that this might deliver 
to specific populations or groups. When public interest and public engagement 
are taken together, the value and vagueness of appeals to public interest become 
less contentious, and the public interest becomes potentially more effective as a 
regulatory device. Thus, meanings of public interest must be captured in context, 
and further life must be breathed into them by active demonstration of how public 
interest in any given situation is properly to be realised.
Finally, proportionality was seen by our participants as a crucial element of 
flexible regulation. While the value of proportionality in regulation is currently 
well-recognised, these results demonstrate that it is much more than a mere 
risk-management tool. Importantly, it involves an ethical assessment of values 
and risks at sake at multiple junctures in the trajectory of conducting research: 
from study design to feedback of results. As with other aspects of regulation, a 
range of actors are therefore implicated in the role that proportionality must play. 
Upstream light-touch ethics review can be thwarted by downstream dispropor-
tionate regulatory requirements, such as required policies on incidental findings 
where such findings are highly unlikely to appear. This study therefore represents 
a call to reimagine proportionality as a regulatory device not merely as a means 
of risk-reduction, but more as a focus for the ethical assessment of the values and 
risks at stake at multiple junctures in the trajectory of conducting research. To do 
so equips actors with a tool to live with—and through—the constant uncertainties 
that typify the domain of human health research.
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